Promising Prospects for CG Oncology’s Cretostimogene in NMIBC Treatment: Superior Efficacy and Strategic Expansion

H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) today and set a price target of $75.00.

Andres Y. Maldonado’s rating is based on several compelling factors surrounding CG Oncology, Inc.’s lead product, cretostimogene (Creto). The therapy has demonstrated superior durability and tolerability compared to its competitor, Johnson & Johnson’s TAR-200, in treating high-risk non-muscle invasive bladder cancer (NMIBC) patients who have failed BCG treatment. Creto’s impressive complete response rates and favorable safety profile, with no Grade ≥3 adverse events, make it a promising option for urology practices aiming to incorporate bladder-sparing immunotherapy.
Additionally, CG Oncology is strategically expanding Creto’s application across the NMIBC spectrum through various ongoing studies. These include trials targeting different patient groups, such as those with papillary-only NMIBC and both BCG-naïve and BCG-exposed patients. The company’s efforts to validate Creto earlier in the treatment paradigm, coupled with the ongoing Phase 3 PIVOT-006 study, highlight its potential as a foundational immunotherapy. These initiatives not only broaden Creto’s commercial reach but also strengthen its position as a versatile treatment option for diverse NMIBC subtypes.

In another report released on May 2, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $41.00 price target.